F-16915

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H37NO2
Molecular Weight	419.5989
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	6
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCC1=CC=CN=C1

InChI

InChIKey=BUWVEXMRBAWBPJ-KUBAVDMBSA-N

InChI=1S/C28H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23-28(30)31-26-27-22-21-24-29-25-27/h3-4,6-7,9-10,12-13,15-16,18-19,21-22,24-25H,2,5,8,11,14,17,20,23,26H2,1H3/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-

HIDE SMILES / InChI

Molecular Formula	C28H37NO2
Molecular Weight	419.5989
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	6
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:44:24 UTC 2023` Edited by `admin` on `Sat Dec 16 11:44:24 UTC 2023`
Record UNII	42L7PA2MAV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

F-16915

Code

English

3-PYRIDYLMETHYL (4Z,7Z,10Z,13Z,16Z,19Z)-DOCOSA-4,7,10,13,16,19-HEXAENOATE

Systematic Name

English

4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, 3-PYRIDINYLMETHYL ESTER, (ALL-Z)-

Systematic Name

English

PYRIDIN-3-YLMETHYL (4Z,7Z,10Z,13Z,16Z,19Z)-DOCOSA-4,7,10,13,16,19-HEXAENOATE

Systematic Name

English

F16915

Code

English

4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, 3-PYRIDINYLMETHYL ESTER, (4Z,7Z,10Z,13Z,16Z,19Z)-

Systematic Name

English

Code System Code Type Description

FDA UNII

42L7PA2MAV

Created by admin on Sat Dec 16 11:44:24 UTC 2023 , Edited by admin on Sat Dec 16 11:44:24 UTC 2023

PRIMARY

CAS

92510-91-3

Created by admin on Sat Dec 16 11:44:24 UTC 2023 , Edited by admin on Sat Dec 16 11:44:24 UTC 2023

PRIMARY

PUBCHEM

14671646

Created by admin on Sat Dec 16 11:44:24 UTC 2023 , Edited by admin on Sat Dec 16 11:44:24 UTC 2023

PRIMARY

Related Record Type Details


					42L7PA2MAV

F-16915

ACTIVE MOIETY

Comments:

The aim of the present study was to investigate the effects of a new pure docosahexaenoic acid derivative called F 16915 in experimental models of heart failure-induced atria dysfunction. The atrial dysfunction-induced AF was investigated (1) in a dog model of tachypacing-induced congestive heart failure and (2) in a rat model of heart failure induced by occlusion of left descending coronary artery and 2 months reperfusion. F 16915 (5 g/day for 4 weeks) significantly reduced the mean duration of AF induced by burst pacing in the dog model (989 +/- 111 s in the vehicle group to 79 +/- 59 s with F 16915, P < 0.01). This dose of F 16915 also significantly reduced the incidence of sustained AF (5/5 dogs in the vehicle group versus 1/5 with F 16915, P < 0.05). In the rat model, the percentage of shortening fraction in the F 16915 group (100 mg/kg p.o. daily) was significantly restored after 2 months (32.6 +/- 7.4 %, n = 9 vs 17.6 +/- 3.4 %, n = 9 in the vehicle group, P < 0.01). F 16915 also reduced the de-phosphorylation of connexin43 from atria tissue. The present results show that treatment with F 16915 reduced the heart dilation, resynchronized the gap junction activity, and reduced the AF duration in models of heart failure.